Cleveland Clinic’s Phase 1 Vaccine Trial Signals New Hope for Aggressive Breast Cancer

Recently, researchers at the globally recognised Cleveland Clinic successfully concluded Phase 1 vaccine trials that activate the immune system against tumour cells of Triple-negative breast cancer (TNBC). TNBC is considered one of the most aggressive and perilous forms of breast cancer that cannot be easily cured with the traditional hormonal or targeted therapies typically used in breast cancer.

After the Phase 1 trial of the vaccine, the clinic released reports indicating promising results. Initial results from this trial showed that about 74% of participants generated a measurable immune response, and the vaccine demonstrated a strong safety profile at the recommended dose. This marks a significant step forward in a field with limited treatment options and particularly poor outcomes for high-risk patients.

However, the Phase 1 studies merely focused on safety and immune activation rather than on preventing cancer recurrence or improving survival outcomes.

Source: ndtv.com